{"name":"Seagen Inc.","slug":"seagen-inc","ticker":"","exchange":"","domain":"seagen.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":904000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Tukysa","genericName":"tucatinib","slug":"tucatinib","revenue":463000000,"yoyGrowth":0,"percentOfTotal":51.2},{"name":"Tisotumab Vedotin","genericName":"tivdak","slug":"tivdak","revenue":147000000,"yoyGrowth":0,"percentOfTotal":16.3},{"name":"Tivdak","genericName":"tisotumab-vedotin","slug":"tisotumab-vedotin","revenue":147000000,"yoyGrowth":0,"percentOfTotal":16.3},{"name":"Tivdak","genericName":"TISOTUMAB","slug":"tisotumab","revenue":147000000,"yoyGrowth":0,"percentOfTotal":16.3}],"timeline":[{"date":"2020-01-01","label":"Tukysa first approved","drug":"Tukysa","drugSlug":"tucatinib","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Tisotumab Vedotin first approved","drug":"Tisotumab Vedotin","drugSlug":"tivdak","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Tivdak first approved","drug":"Tivdak","drugSlug":"tisotumab-vedotin","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Tivdak first approved","drug":"Tivdak","drugSlug":"tisotumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":904000000,"percentOfTotal":100,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Tukysa","genericName":"tucatinib","slug":"tucatinib","indication":"Metastatic human epidermal growth factor 2 positive carcinoma of breast","status":"marketed","revenue":463000000},{"name":"Tisotumab Vedotin","genericName":"tivdak","slug":"tivdak","indication":"Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","status":"marketed","revenue":147000000},{"name":"Tivdak","genericName":"tisotumab-vedotin","slug":"tisotumab-vedotin","indication":"Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","status":"marketed","revenue":147000000},{"name":"Tivdak","genericName":"TISOTUMAB","slug":"tisotumab","indication":"recurrent or metastatic cervical cancer with disease progression on or after chemotherapy","status":"marketed","revenue":147000000},{"name":"ARRY-380, HER2 inhibitor; oral","genericName":"ARRY-380, HER2 inhibitor; oral","slug":"arry-380-her2-inhibitor-oral","indication":"Breast cancer","status":"phase_1"},{"name":"Taxotere (docetaxel)","genericName":"Taxotere (docetaxel)","slug":"taxotere-docetaxel","indication":"Breast cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"SEA-CD40","genericName":"SEA-CD40","slug":"sea-cd40","indication":"Other","status":"phase_2"},{"name":"SGN-15, Docetaxel","genericName":"SGN-15, Docetaxel","slug":"sgn-15-docetaxel","indication":"Other","status":"phase_2"},{"name":"SGN-35","genericName":"SGN-35","slug":"sgn-35","indication":"Other","status":"phase_2"},{"name":"SGN-CD19A","genericName":"SGN-CD19A","slug":"sgn-cd19a","indication":"Other","status":"phase_1"},{"name":"SGN-CD33A","genericName":"SGN-CD33A","slug":"sgn-cd33a","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Tukysa","genericName":"tucatinib","slug":"tucatinib","phase":"marketed","mechanism":"Tukysa works by blocking the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells.","indications":["Metastatic human epidermal growth factor 2 positive carcinoma of breast"],"catalyst":""},{"name":"Tisotumab Vedotin","genericName":"tivdak","slug":"tivdak","phase":"marketed","mechanism":"Tissue factor","indications":["Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy"],"catalyst":""},{"name":"Tivdak","genericName":"tisotumab-vedotin","slug":"tisotumab-vedotin","phase":"marketed","mechanism":"Tisotumab vedotin is a tissue factor (TF)-directed antibody drug conjugate that targets and disrupts microtubule networks in cancer cells.","indications":["Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy"],"catalyst":""},{"name":"Tivdak","genericName":"TISOTUMAB","slug":"tisotumab","phase":"marketed","mechanism":"Tivdak works by binding to a specific target on cancer cells, triggering an immune response to destroy the cancer.","indications":["recurrent or metastatic cervical cancer with disease progression on or after chemotherapy"],"catalyst":""},{"name":"ARRY-380, HER2 inhibitor; oral","genericName":"ARRY-380, HER2 inhibitor; oral","slug":"arry-380-her2-inhibitor-oral","phase":"phase_1","mechanism":"HER2 inhibitor","indications":["Breast cancer"],"catalyst":""},{"name":"SEA-CD40","genericName":"SEA-CD40","slug":"sea-cd40","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SGN-15, Docetaxel","genericName":"SGN-15, Docetaxel","slug":"sgn-15-docetaxel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SGN-35","genericName":"SGN-35","slug":"sgn-35","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SGN-CD19A","genericName":"SGN-CD19A","slug":"sgn-cd19a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SGN-CD33A","genericName":"SGN-CD33A","slug":"sgn-cd33a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Taxotere (docetaxel)","genericName":"Taxotere (docetaxel)","slug":"taxotere-docetaxel","phase":"phase_3","mechanism":"Taxotere (docetaxel) works by inhibiting cell division, ultimately leading to cell death in rapidly dividing cancer cells.","indications":["Breast cancer","Non-small cell lung cancer","Prostate cancer","Stomach cancer","Head and neck cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxObS1GQzBWU3JTOUlXaXRoaXp5X1lkYTVJNkFOOTk4NGI3WVZaQXY2U19HdlZSWWwyXzQ1RFlaQXZsS0xGOWlNRzFTcG90eDNMa1dJR3RqWElBQTA5SGIxYVcxb3hQSGx1dVhiLVUyNDRDbElscFAwQnJQb0pSbVFKN3pLakhWamxLNUVWNWt1LWtQM2hPUS04d2hrc0U3WXdPZ2FueEI1WE1pTlZTMHQyQTJTY0dibHRKR1JDNUE5aw?oc=5","date":"2026-01-04","type":"deal","source":"AD HOC NEWS","summary":"The Truth About Seagen Inc (Acquired): Why Wall Street Moved On But The Story Isn’t Over - AD HOC NEWS","headline":"The Truth About Seagen Inc (Acquired): Why Wall Street Moved On But The Story Isn’t Over","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcUhXanpvN3F3cXlFWW9sc3plUzMtZUlfazZCU1Voc1lNSE1iWVdiam1RSl9rNVlRVE4yTUtwdmg5NkxNUHlhT0x3YWNNRmFmYzFldU9iSkxtSFZ3YzdwY1lDMm95dFNObTlLVWx3ME5TMmRQTUZUTzBiLThac3RPb29McEpVR2JGU1c3LXRWd0NRa3NJTm9vTkppZVRsdlVFNkNWUlpZeThUUVlYZzF3U0Z4TFNZZE5vV0tQeHV4czYxZw?oc=5","date":"2025-12-03","type":"patent","source":"Fierce Pharma","summary":"Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict - Fierce Pharma","headline":"Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPcEpLWkZuUGl4NE16SEZILWI4QkZHMGtQS0gwc1lzX2tueE93dnd4eHhhdDMxbGRLdlN6UmhrWUR6bGZtS3R5OGdESTZRc3BlWHF3cHJtbTFjNmRMRVR4dE1NM3RQelktdDlwZDZxTC1ZZkZ0Z2NEb0xfZzhEOW5OaHQ5TElMZVRqaXdkekpPNEdjVm5POU5oeGhDdkduLVN2WlctN0pUcVpSeTVMQmJ3S01LQWhOZXMtSnlr?oc=5","date":"2025-09-03","type":"deal","source":"People Matters SEA","summary":"Pharma giant Pfizer to acquire Seagen for $43 billion - People Matters SEA","headline":"Pharma giant Pfizer to acquire Seagen for $43 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOSmtWbnh6T09HbF9iRUlRSGVjWTllVUhYcVZvYkpjV2RBci1ObzdvRkZ2OXRsY193LTFFa3p6MWc5R0xsX0dxN1ZselZZcFdPU0tWSU5USVZmc1Bsc21mT2dvVHpyakxkRDgzRkc3ZlBhaUQwZlg1b3psYm5Zc2NwUWNBWjJKQTZfRWhKaEhn?oc=5","date":"2023-12-14","type":"pipeline","source":"Contract Pharma","summary":"Pfizer Completes $43B Seagen Acquisition - Contract Pharma","headline":"Pfizer Completes $43B Seagen Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQVjhtdzRSVDNxS20yUUZ5a3p6enZGZXdKdVd0bE90NXl4cmZDY21vVjVBSld4Q2VFd3hRa3V4dHIxYU9kc3RRWkVXX0JRRnoyeURkSkUtdHNnbDRyVXM5aTB0cngzcDAzaWFITFQ1MmtqUGt1WXBmSHhrMTRFZFN4ZDR3S0w2TnFheldMTUVTZnZCeVNrNE92aVlDbjdOUmNjLWZjOWlIY01zdDJ4Z0p6dy1iZlJ3NTg?oc=5","date":"2023-12-14","type":"deal","source":"Fierce Pharma","summary":"Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline - Fierce Pharma","headline":"Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPT2lwS3JpMlFnNHZidXM1V1I2bklnNkNLSk5vT0NNNmc0MzVIRUZuTks4TmFhakFxX05JemdpRUpTSF95UURWck9zemVSeDVBdTA0dWFWZ0F1SnZRQlVtZ2YzM2lBZWFiZzFtV25jMjJyejByWVlrLV94UWNSSVpYMkZ6cGRmQkoySTlDb2pvSWFpS3Y4c0JsbXFuX0FLRDjSAaQBQVVfeXFMTXB1WHZUZi1FaFplb0JJU3lncU54WWhzZVdGQ3JSanljaEZsX181SXhPcGFBbE1nRXh0UGpOOVF6S2pSb0RyVWVUQjZjUXBsaTJHM1VESGhrMmdtTWZCdWloXzFaSkJzNWRoTFY2emVleG9uQ1VVd2RlUjVrcWQ0RFdGa3hYQTAyZ1ZLbTFWZzVpUzNNb0JmOS1lOE5La2J3RkRlUGY?oc=5","date":"2023-03-13","type":"deal","source":"PBS","summary":"Pfizer buys Seagen for $43 billion, seeks new cancer treatments - PBS","headline":"Pfizer buys Seagen for $43 billion, seeks new cancer treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOejB3NlNJWFJiOGFqVmlDTlFsUnpiQVhlTEtNUVl5SHp0MUwtbnllTFhzT2dyRzAxVWJ1WkNhbzdMZVVVVmZIZDVhUXZZSmtKTHVPQWdVaU1jYmR3Mi1naWZHZ2RDZ1QzdlVfbV85VlBZQ3JyX0NHOFVaa292cmJ0cFl4MkRvT3BRQkFwYmhrUENLLUU?oc=5","date":"2023-03-13","type":"deal","source":"BioPharma Dive","summary":"Pfizer to buy Seagen in $43B cancer drug deal - BioPharma Dive","headline":"Pfizer to buy Seagen in $43B cancer drug deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNZkdvYzJxNVJWNGFWM0w3MWgwclAzYUtGQ09iZVdMTF9wQUVVMEJMUGpZZmJUTFpPQ2F2aUFBYUNmUzVNRXp5cnBfWFBwOFJjY2NiS3Vsd3dXdkFvTGkzOVZLYkpyZVhoZmxKbXFma3lvbG9UT0xTRjhPNzFMaVhzRG5XMDnSAYoBQVVfeXFMUFVnd1dtRzFqM25oRGY2MGVGMm9kV1pMM2dUUHNTeWNSc2dQSzZOb01BdGpkUVpFam45ek5xbkNndEY3cHlLX2lVZkNDQVQ5QWJIZEFpdXpyZ2NNS3NENnFNZklQZGE0SF9aVWFvdWpfWnp6MU16ZmJGZDYwWjVjaU42UTlIajZPQTZ3?oc=5","date":"2023-03-13","type":"deal","source":"CBS News","summary":"Pfizer to buy Seagen for $43B to enhance reach of cancer drugs - CBS News","headline":"Pfizer to buy Seagen for $43B to enhance reach of cancer drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNMjlBZ1AzaENMdHdLUUhtel9rWGw3MlB3ZmFPN3h6YVkxaVg1bEV1TlVnV0FCRi1ZTDJ6V1FSTFBYazRwcDZVOGVOTVhYU3JkdmZxdlg0c1dfQTZaV0tkOUM0cHNKY0V0Tm5VQlZKN3ZHN1k3M19sN3NneExyRVNjUXl0NV9qbkl0bnp5ZThB?oc=5","date":"2023-03-13","type":"deal","source":"WSJ","summary":"Pfizer Agrees to Buy Seagen for $43 Billion - WSJ","headline":"Pfizer Agrees to Buy Seagen for $43 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOTms3SVN5UlRSeUtJUkRsanRmaWw2UWhXWjV0dWNLTTBaN0NmNXMtRS01TUxpNC1KMXRyRWJZalo3eTRoMkFnc3F0TWIxTHBwbDhwRE5GUWhjWjhEaGtBVk9jVXV1WG82czNreC10VGdFdTQ3ajFTak9NanFuTWl2akp1THVpZzJBNkIwSTJ4UzEwUQ?oc=5","date":"2023-02-27","type":"deal","source":"WSJ","summary":"Exclusive | Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion - WSJ","headline":"Exclusive | Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPaFBydXR3S1ZwV3J1ZkhCNFFoQ1E0anR5ZTB0N1ZpNGx3bEVfWWlpNHRKckd6TmJySW1OV09aaG5JTkZWNEJTYjJPbzlHWVV2TmJDVG9iQnNQY2pMUW5lZVluczVMYTJVM1dVb0hDWUJmREhTQWVhYXRuTEF4RkY4Sl9xODcyRDYyY0J3VW5UN2NSbmh0Y3o1NFJ5b3lDWUFXNGxPNWE5QmhaLUhJV1o5SlVJSFc?oc=5","date":"2022-08-26","type":"deal","source":"Bloomberg.com","summary":"Merck’s Talks to Acquire Seagen Hit Snag Over Price - Bloomberg.com","headline":"Merck’s Talks to Acquire Seagen Hit Snag Over Price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxORU5OS0hFQlp6OWFLOWg3dUtYU1MycVhvVVVDNThmUkR1LVFST1NhRkxLZmFIVnlPUHc2T1R6Vlo0WXBtUDlxY0NsNzh6cTM5T0Vpai0yUWJ3U0ZVTko1R1lmb0E2b2I5OFRJZVgtbDFNMmRjcndMQjh5Wmh2cWdad2FuNnlRaVhYOUtXWlZBQnRDdk5Tdmg2MXVaYXBPTUMtck84UHhlU0pnYzRaVnp3Zy1fNnVqUEpOcE1F?oc=5","date":"2022-08-04","type":"pipeline","source":"TechTarget","summary":"Merck & Co.'s $40B Acquisition of Pharmaceutical Company Seagen - TechTarget","headline":"Merck & Co.'s $40B Acquisition of Pharmaceutical Company Seagen","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"marketed":4,"phase_1":3,"phase_2":3,"phase_3":1},"enrichmentLevel":0,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}